How PRIMO and TERZO Could Shift Community Practice

Brammer reflects on how pivotal phase 3 evidence has historically changed clinical behavior and why emerging duvelisib data may follow a similar path. Drawing on his experience with brentuximab vedotin, he recalls that once definitive frontline data became available, community physicians grew more willing to treat peripheral T-cell lymphoma themselves rather than routinely referring patients to academic centers. He suggests that the PRIMO results, and especially the anticipated TERZO findings, could prompt a comparable shift, broadening the number of clinicians comfortable managing these diseases and improving access for patients treated outside specialized institutions. At the same time, both experts acknowledge that considerable nuance remains in selecting and sequencing therapy, even within seemingly defined groups such as CD30-positive lymphomas. The segment frames robust randomized evidence not only as a route to regulatory approval but as a practical catalyst for changing how and where patients with peripheral T-cell lymphoma receive care.